The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The surge in dopamine in ventral striatal regions in response to drugs of abuse and drug-associated stimuli is a final common pathway of addiction processes. GABA B agonists exert their effects indirectly, by quieting dopaminergic afferents. The ability of the GABA B agonist, baclofen to ameliorate nicotine and drug motivated behavior is established within the animal literature, however its potential to do so in humans is understudied, particularly with respect to its possible utility as a smoking cessation agent. We conducted a nine-week double-blind placebo-controlled pilot trial of baclofen for smoking reduction (N=30/group) in smokers contemplating, but not quite ready to quit. Baclofen was titrated upwards to 20 mg q.i.d. over a period of twelve days. The primary outcome measure was the number of cigarettes smoked per day (CPD). A significant group by time effect of medication was observed. Baclofen was superior to placebo in reducing CPD (β=0.01, t=1.97, p<0.05). The most common side effect reported during baclofen treatment is transient drowsiness, however there were no differences between groups in mild, moderate, or severe sedation. Craving was significantly lowered at end of treatment in all smokers (p<0.02). Retention did not differ between groups. In line with a multitude of preclinical studies examining the effects of baclofen on drug-motivated behavior, baclofen reduced CPD. In agreement with other studies examining craving and drug use, reductions in CPD were accompanied by a reduction in craving, a major motivator underlying continued smoking and relapse. These preliminary results demonstrate provisional evidence of the utility of baclofen to aid in smoking cessation and indicate further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598
Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction
Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Childress, A.-R., Jayne, M., Ma, Y., & Wong, C. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-06.2006 · Cited by 1,164 · cited 1×
“At least two studies reported that cocaine cues elicit craving and increased dopamine release in the striatum of cocaine addicted individuals (Volkow et al., 2006; Wong et al., 2006).”
BackgroundSelf-citationSmoking cessation with and without assistance
Zhu, S.-H., Melcer, T., Sun, J., Rosbrook, B., & Pierce, J. P. (2000) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(00)00124-0 · Cited by 405
Increased Occupancy of Dopamine Receptors in Human Striatum during Cue-Elicited Cocaine Craving
Wong, D. F., Kuwabara, H., Schretlen, D. J., Bonson, K. R., Zhou, Y., Nandi, A., Brašić, J. R., Kimes, A. S., Maris, M. A., Kumar, A., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301194 · Cited by 311
The effect of bupropion on nicotine craving and withdrawal
Shiffman, S., Johnston, J. A., Khayrallah, M., Elash, C. A., Gwaltney, C. J., Paty, J. A., Gnys, M., Evoniuk, G., & DeVeaugh-Geiss, J. (2000) · Psychopharmacology · doi:10.1007/s002130050022 · Cited by 259
Boileau, I., Dagher, A., Leyton, M., Welfeld, K., Booij, L., Diksic, M., & Benkelfat, C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4370-06.2007 · Cited by 222
A meta-analysis of the efficacy of over-the-counter nicotine replacement
Hughes, J. R., Shiffman, S., Callas, P., & Zhang, J. (2003) · Tobacco Control · doi:10.1136/tc.12.1.21 · Cited by 203
West, R., Baker, C. L., Cappelleri, J. C., & Bushmakin, A. G. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1041-3 · Cited by 203
Cited by
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Le Foll, B., Piper, M. E., Fowler, C. D., Tonstad, S., Bierut, L., Lu, L., Jha, P., & Hall, W. D. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00346-w · Cited by 316
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice
Aubin, H., Luquiens, A., & Berlin, I. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12116 · Cited by 138
“A recent randomised placebocontrolled pilot trial demonstrated a significant reduction in craving and smoking [143], and another randomised placebo-controlled trial is underway (ClinicalTrials.”
BackgroundSmoking reduction interventions for smoking cessation
Lindson, N., Klemperer, E., Hong, B., Ordóñez-Mena, J. M., & Aveyard, P. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013183.pub2 · Cited by 133
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Metadata
- Authors
- Franklin, T. R., Harper, D., Kampman, K., Kildea-McCrea, S., Jens, W., Lynch, K. G., O’Brien, C. P., & Childress, A. R.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 103
- Issue
- 1-2
- Pages
- 30-36
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2002395747
- Cited by
- 105
- References
- 12
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2009.02.014
- The paper
- Franklin, T. R., Harper, D., Kampman, K., Kildea-McCrea, S., Jens, W., Lynch, K. G., O’Brien, C. P., & Childress, A. R. (2009). The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2009.02.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.